By staff writers

July 17, 2019 -- Nationwide Laboratory Services is set to create a laboratory-developed test using the DNA-based platform of PathogenDx, with the aim of offering fungal testing results in six hours or less, as opposed to the standard time of more than 72 hours with plating cultures.

The two companies are collaborating on the development of a test for use in dermatology and podiatry, and Nationwide will manage the validation and launch of services. The partners aim to have a multiplex fungal assay that can identify up to 44 different pathogens at a time in beta testing by the first quarter of 2020.

For Nationwide, the partnership means the ability to offer rapid testing for multiple pathogens in one multiplex test, and for PathogenDx, it paves the way for entry into the medical microbial testing market, the companies said in a statement. PathogenDx currently has a foothold for its DNA-based testing platform in the food, cannabis, agriculture, and environmental safety industries.

iCubate's iC-GN gram-negative assay clears FDA
iCubate has announced that its iC-GN assay has been cleared by the U.S. Food and Drug Administration (FDA) for use with its iCubate multiplex polymerase...
T2Bacteria panel proves itself, but will hospitals buy in?
The T2Bacteria panel was accurate and fast for detecting five common kinds of bacteria in the blood in a multicenter study published May 13 in the Annals...
Labs gear up to diagnose novel fungal infection
Clinical laboratories are being advised by the U.S. Centers for Disease Control and Prevention on how to handle a relatively new fungal infection, Candida...

Copyright © 2019

Last Updated np 7/17/2019 2:57:56 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.